Hepatitis C News and Research

Latest Hepatitis C News and Research

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Frontier Global awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award

Frontier GeoSciences announced today it was awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award. Frontier was nominated by Oak Ridge National Laboratory staff, who say Frontier's employees have gone "above and beyond" to ensure their programmatic needs and permit requirements are met, related to environmental sampling and analysis.

27 Mar 2010

Innovative biotechnology leading to better understanding of complex diseases

As recently stated in the Glenville Democrat, innovative biotechnology is leading to a greater understanding of complex diseases and better tools for diagnosing and treating conditions such as heart disease, cancer and diabetes.

27 Mar 2010

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Inverness Medical Deutschland GmbH today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in the key European markets of Germany, Austria and Switzerland.

26 Mar 2010

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

ADVENTRX Pharmaceuticals, Inc. today announced that it will meet the U.S. Food and Drug Administration in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.

26 Mar 2010

Substance abuse treatment services: Routine on-site infectious disease screening necessary

Fewer than half of all substance abuse treatment facilities surveyed nationwide reported that they conduct on-site infectious disease screening, according to a new study sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA).

26 Mar 2010

New study questions effectiveness of national Silver Alert program

A group of Miami University researchers studying the national Silver Alert program for locating missing adults with dementia or other cognitive impairments question the program's effectiveness and safety, given the speed in which it's being implemented throughout the country.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

New research may help advance treatment strategies for common liver disease

A research article published in the journal PloS Pathogens could lead to improvements in the production of vaccines for hepatitis A, the most widespread viral disease in the world.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Standard HCV therapy less effective in urban minority patients: Study

A recent study confirms that the standard hepatitis C therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

26 Mar 2010

Hepatitis C treatment less effective in urban minority patients

A recent study confirms that the standard hepatitis C (HCV) therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

China Biologic Products' fourth quarter revenue rises 185.6%

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for the fourth quarter and year ended December 31, 2009.

24 Mar 2010

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

23 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2009 and provided an update on various corporate developments.

23 Mar 2010

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

A team led by researchers from North Carolina State University has published a paper that describes the use of a technique called atomic layer deposition to incorporate "biological functionality" into complex nanomaterials, which could lead to a new generation of medical and environmental health applications. For example, the researchers show how the technology can be used to develop effective, low-cost water purification devices that could be used in developing countries.

23 Mar 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Maryland Technology Enterprise Institute director receives President's Award

WinRho SDF for ITP: Cangene announces new safety information

Frontier Global awarded Oak Ridge National Laboratories 2009 Small Business of the Year Award

Innovative biotechnology leading to better understanding of complex diseases

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530

Substance abuse treatment services: Routine on-site infectious disease screening necessary

New study questions effectiveness of national Silver Alert program

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

New research may help advance treatment strategies for common liver disease

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Standard HCV therapy less effective in urban minority patients: Study

Hepatitis C treatment less effective in urban minority patients

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

China Biologic Products' fourth quarter revenue rises 185.6%

EMA validates InterMune's pirfenidone MAA for IPF

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in